Burning Technology, February 22nd (Ange)On February 22, the Shenzhen Stock Exchange issued a regulatory letter to Jiu’an Medical, stating that during the continuous stock price fluctuations, the company’s replies and investor relations activity record sheets published on the interactive platform were inaccurate and incomplete for many times. The above behavior violates relevant regulations. It is hoped that the company and all directors, supervisors and senior management personnel will learn from the lessons and make rectifications in a timely manner to prevent the recurrence of the above-mentioned problems.
On January 7, 2022, Jiu’an Medical disclosed the “Announcement on the Subsidiary’s Receipt of the iHealth New Crown Antigen Home Self-Assessment OTC Kit for Omicron Variation Virus Testing Performance Experimental Report” (hereinafter referred to as the “Announcement”), stating that the company received the U.S. The RADx project of the National Institutes of Health arranged by the FDA reported on the test performance of the iHealth new crown antigen home self-test OTC kit for Omicron variant virus. The report shows that the iHealth kit detected 100% of the maximum CT value in the experiment. 21.59 (n=5) of Omicron active virus samples. On January 15, 2022, Jiu’an Medical said in reply to the letter of concern of the Shenzhen Stock Exchange that the aforementioned experiment “positive detection rate of all samples in the experimental group: all samples can be detected when the CT value is ≤ 21.59, and 60% can be detected when the CT value is 22.86. It cannot be detected at all when the CT value is ≥23.87.” The Shenzhen Stock Exchange believes that Jiu’an Medical’s information disclosure of the experimental results in the “Announcement” on January 7, 2022 was incomplete.
On December 1, 2021, Jiu’an Medical responded to investors’ questions on the interactive platform and said, “As of now, our company’s new crown detection reagents have ranked first in Amazon’s US website sales.”
On December 29, 2021, Jiu’an Medical said in response to the Shenzhen Stock Exchange’s letter of concern, “Amazon’s US sales ranking is a comprehensive ranking of daily sales and instantaneous sales, and the ranking will be updated in real time, and does not represent cumulative sales. “.
On December 21, 2021, Jiu’an Medical responded to investors’ questions on product quality issues reflected by Amazon’s US consumers on the interactive platform, saying, “Although our kits have a small proportion of sales in Amazon’s US”, and later On December 22, 2021, it was corrected to “Although the number of quality feedback problems of this product in Amazon US accounts for a small proportion of Amazon US sales”, the content and meaning of the words before and after the correction are quite different.
On December 30, 2021, Jiu’an Medical stated in the investor relations activity record sheet published on the interactive platform that “Joo’an Medical holds 80% of the shares of iHealth America, the main body of the test kit sales”, which was reviewed and supervised by the Shenzhen Stock Exchange afterwards. , corrected to “Joan Medical holds 70.46% of the shares of iHealth America, the main body of the test kit sales”.
The Shenzhen Stock Exchange believes that in December 2021, the stock price of Jiu’an Medical has increased by 161.34%, and it has hit the abnormal fluctuation standard of stock trading five times during the period. During the period of continuous stock price changes, Jiu’an Medical’s replies and investor relations activity record sheets published on the interactive platform were inaccurate and incomplete for many times.
Jiu’an Medical has obtained huge profits from the development of iHealth kits, which has brought great changes to the company’s revenue and net profit, and has also become a star in the capital market. From the perspective of stock price, Jiu’an Medical has achieved 28 daily limits within 46 trading days from November 15, 2021, and the stock price has soared from 6.8 yuan per share to the highest of 88.88 yuan per share, an increase of as much as 12 times.
The market opened on February 22, and Jiu’an Medical opened at a price of 70 yuan per share. As of 11:00 in the morning, the stock price fell 6.13% to 68.63 yuan per share. On February 21, Jiu’an Medical’s daily limit was 73.1 yuan per share.Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.